Want to see FR:ALSEN full AI Analyst Report?
ALSEN Stock Chart & Stats
€0.27
€0.02(8.47%)
At close: 4:00 PM EDT
€0.27
€0.02(8.47%)
Day’s Range― - ―
52-Week Range€0.22 - €0.81
Previous CloseN/A
Volume1.22M
Average Volume (3M)679.00K
Market Cap
€117.52M
Enterprise Value€55.00
Total Cash (Recent Filing)€47.46M
Total Debt (Recent Filing)€1.28M
Price to Earnings (P/E)―
Beta0.90
Next Earnings
Sep 23, 2026EPS Estimate
-0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.10
Shares Outstanding515,648,600
10 Day Avg. Volume646,265
30 Day Avg. Volume679,005
Financial Highlights & Ratios
PEG Ratio-0.49
Price to Book (P/B)2.28
Price to Sales (P/S)0.00
P/FCF Ratio-3.66
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€1.00Price Target Upside270.37% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.02
Revenue Forecast (FY)€21.86M
Bulls Say, Bears Say
Bulls Say
Low LeverageModest debt and generally small debt-to-equity reduce fixed financial obligations and preserve flexibility while Sensorion funds development. This gives the company more room to prioritize programs or secure capital without carrying the burden of a heavily leveraged balance sheet.
Focused Inner-ear PipelineA specialized focus on inner-ear diseases gives Sensorion a clear therapeutic identity and supports concentrated research effort. Its work across gene therapy and other approaches may create multiple routes to address unmet needs and provide partnership or licensing opportunities.
Prior Revenue GenerationThe 2020–2024 revenue expansion shows that Sensorion previously generated increasing income from its activities before the 2025 disruption. Strong gross profit when revenue existed suggests the underlying revenue model can support attractive economics if development-related income resumes.
Bears Say
Revenue DisruptionA drop to zero annual revenue removes current operating income and demonstrates that Sensorion’s revenue stream is not yet dependable. For the next several quarters, the company must advance its programs or partnerships without an established recurring commercial revenue base.
Persistent Operating LossesLarge recurring operating and net losses show that Sensorion remains far from self-funded profitability. Continued investment without meaningful operating leverage can pressure equity value, constrain strategic choices, and make successful clinical or partnering outcomes increasingly important.
Sustained Cash BurnDeeply negative operating and free cash flow indicate that the business consumes substantial cash to maintain research activities. This makes external funding central to the operating model and leaves the company exposed to financing needs before products generate recurring revenue.
Sensorion SAS News
ALSEN FAQ
What was Sensorion SAS’s price range in the past 12 months?
Sensorion SAS lowest stock price was €0.22 and its highest was €0.81 in the past 12 months.
What is Sensorion SAS’s market cap?
Sensorion SAS’s market cap is €117.52M.
When is Sensorion SAS’s upcoming earnings report date?
Sensorion SAS’s upcoming earnings report date is Sep 23, 2026 which is in 9 days.
How were Sensorion SAS’s earnings last quarter?
Sensorion SAS released its earnings results on Mar 18, 2026. The company reported -€0.04 earnings per share for the quarter, beating the consensus estimate of -€0.06 by €0.02.
Is Sensorion SAS overvalued?
According to Wall Street analysts Sensorion SAS’s price is currently Undervalued.
Does Sensorion SAS pay dividends?
Sensorion SAS does not currently pay dividends.
What is Sensorion SAS’s EPS estimate?
Sensorion SAS’s EPS estimate is -0.03.
How many shares outstanding does Sensorion SAS have?
Sensorion SAS has 515,648,600 shares outstanding.
What happened to Sensorion SAS’s price movement after its last earnings report?
Sensorion SAS reported an EPS of -€0.04 in its last earnings report, beating expectations of -€0.06. Following the earnings report the stock price went down -12.651%.
Which hedge fund is a major shareholder of Sensorion SAS?
Currently, no hedge funds are holding shares in FR:ALSEN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Sensorion SAS
Sensorion SA is a clinical-stage biopharmaceutical firm based in Montpellier, France, specializing in the development of therapies for inner ear disorders. Their key initiatives include gene therapy programs: OTOF-GT, designed to restore hearing for individuals with Otoferlin deficiency, and USHER-T1-GT, targeting Usher syndrome Type 1. The company also advances SENS-401, a drug candidate for treating sudden sensorineural hearing loss. Sensorion's broader pipeline encompasses numerous experimental treatments aimed at restoring, treating, and preventing various conditions affecting the inner ear. They hold a collaboration agreement with Institut Pasteur concerning gene therapy for both pediatric and adult deafness. Additionally, Sensorion partners with Sonova Holding AG to integrate genetic analysis into the routine diagnosis of progressive adult hearing loss, combining advanced therapeutic approaches with traditional hearing aids. Founded in 2009, Sensorion SA operates primarily in France.
ALSEN Stock 12 Month Forecast
Average Price Target
€1.00
▲(270.37% Upside)